Xue-Lin Xiang, Xiang-Kun Zhan, Qiang Xia, Department of Liver Surgery, Renji Hospital (Punan Branch), Shanghai 200127, China
Yi-Chi Wu, Department of Liver Surgery, Renji Hospital (Punan Branch), School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Zi-Jie Zhang, Ying Tong, June-Kong Yong, Yi Zhou, Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
Hao Feng, Department of Liver Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Institute of Transplantation, Shanghai Engineering Research Center of Transplantation and Immunology, Shanghai 200127, China
Co-first authors: Xue-Lin Xiang and Yi-Chi Wu.
Co-corresponding authors: Yi Zhou and Hao Feng.
Author contributions: Xiang XL and Wu YC did the research and writing of the manuscript, they contributed equally to this article, they are the co-first authors of this manuscript; Zhang ZJ, Zhan XK, Tong Y, and Yong JK assisted in the writing of the draft and final paper; Feng H and Xia Q were responsible for the conception and design of the study; Zhou Y and Feng H have played important and indispensable roles in the manuscript preparation, they contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
AI contribution statement: ChatGPT (from OpenAI, version GPT-5.3) and Gemini were utilized to assist in summarizing existing literature, and enhancing the fluency and English language quality of the article. Figures 2 and 3 were generated by BioRender AI and then manually optimized by the authors.
Supported by Shanghai Science and Technology Development Foundation (Outstanding academic leader), No. 23XD1423100; and National Natural Science Foundation of China, No. 82672320.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Hao Feng, MD, PhD, Associate Research Scientist, Deputy Director, Principal Investigator, Department of Liver Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Institute of Transplantation, Shanghai Engineering Research Center of Transplantation and Immunology, No. 160 Pujian Road, Shanghai 200127, China. surgeonfeng@live.com
Received: April 23, 2026 Revised: June 1, 2026 Accepted: October 16, 2026 Published online: November 27, 2026 Processing time: 212 Days and 2.8 Hours
Core Tip
Core Tip: Post-transplant hepatocellular carcinomarecurrence occurs in 8%-20% of recipients, mainly within 2 years. Key drivers include immunosuppression, tumor biology, and ischemia-reperfusion injury. Risk factors are beyond Milan criteria, microvascular invasion, and high alpha-fetoprotein. Surveillance uses imaging and alpha-fetoprotein, with circulating cell-free DNA-minimal residual diseaseenabling earlier detection. Oligorecurrence benefits from resection or ablation. Advanced disease is treated with tyrosine kinase inhibitors, while immune checkpoint inhibitors risk rejection. Adjuvant lenvatinib improves recurrence-free survival in high-risk patients. artificial intelligence-based models enhance prediction, but evidence remains largely retrospective, requiring prospective trials.